S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ABCL

AbCellera Biologics (ABCL) Stock Price, News & Analysis

$4.53
+0.04 (+0.89%)
(As of 03/28/2024 ET)
Today's Range
$4.49
$4.65
50-Day Range
$4.29
$5.59
52-Week Range
$3.87
$8.05
Volume
928,914 shs
Average Volume
1.45 million shs
Market Capitalization
$1.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.86

AbCellera Biologics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
250.0% Upside
$15.86 Price Target
Short Interest
Bearish
11.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.16mentions of AbCellera Biologics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.64) to ($0.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.56 out of 5 stars

Medical Sector

698th out of 938 stocks

Pharmaceutical Preparations Industry

312th out of 417 stocks

ABCL stock logo

About AbCellera Biologics Stock (NASDAQ:ABCL)

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ABCL Stock Price History

ABCL Stock News Headlines

The 7 Best Penny Stocks to Buy in Q2 2024
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
AbCellera: Victim Of Its Own Success
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Piper Sandler Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
AbCellera Announces Resignation of Board Member
ABCL Mar 2024 4.000 call
ABCL Mar 2024 5.000 call
Stifel Nicolaus Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
Q4 2023 Abcellera Biologics Inc Earnings Call
Recap: AbCellera Biologics Q4 Earnings
AbCellera Reports Full Year 2023 Business Results
See More Headlines
Receive ABCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ABCL
Fax
N/A
Employees
586
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.86
High Stock Price Target
$24.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+251.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-146,400,000.00
Net Margins
-384.99%
Pretax Margin
-457.67%

Debt

Sales & Book Value

Annual Sales
$38.03 million
Book Value
$3.97 per share

Miscellaneous

Free Float
197,774,000
Market Cap
$1.32 billion
Optionable
Optionable
Beta
0.38
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Carl L.G. Hansen Ph.D. (Age 49)
    CEO, President & Chairperson
    Comp: $711.47k
  • Mr. Andrew Booth M.B.A.Mr. Andrew Booth M.B.A. (Age 50)
    Chief Financial Officer
    Comp: $642.42k
  • Dr. Veronique Lecault Ph.D. (Age 39)
    COO & Director
    Comp: $645.07k
  • Mr. Tryn T. Stimart Esq. (Age 54)
    J.D., Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer
    Comp: $644.4k
  • Mr. Neil Aubuchon M.B.A. (Age 54)
    Chief Commercial Officer
    Comp: $684.81k
  • Marcie Thiessen CPA
    CGA, Senior Director of Finance & Accounting
  • Dr. Ester Falconer Ph.D. (Age 49)
    Chief Technology Officer
  • Josephine Hellschlienger Ph.D.
    Manager of Investor Relations
  • Kathleen Reid B.A.
    Head of Corporate Communications
  • Graham Craig M.Sc.
    Director of Corporate Development

ABCL Stock Analysis - Frequently Asked Questions

Should I buy or sell AbCellera Biologics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABCL shares.
View ABCL analyst ratings
or view top-rated stocks.

What is AbCellera Biologics' stock price target for 2024?

7 Wall Street analysts have issued 12 month target prices for AbCellera Biologics' stock. Their ABCL share price targets range from $6.00 to $24.00. On average, they anticipate the company's share price to reach $15.86 in the next year. This suggests a possible upside of 250.0% from the stock's current price.
View analysts price targets for ABCL
or view top-rated stocks among Wall Street analysts.

How have ABCL shares performed in 2024?

AbCellera Biologics' stock was trading at $5.71 at the beginning of the year. Since then, ABCL shares have decreased by 20.7% and is now trading at $4.53.
View the best growth stocks for 2024 here
.

When is AbCellera Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ABCL earnings forecast
.

How were AbCellera Biologics' earnings last quarter?

AbCellera Biologics Inc. (NASDAQ:ABCL) released its earnings results on Tuesday, February, 20th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.03. The business earned $9.18 million during the quarter, compared to the consensus estimate of $9.58 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 12.36% and a negative net margin of 384.99%.

What ETFs hold AbCellera Biologics' stock?

ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ).

When did AbCellera Biologics IPO?

AbCellera Biologics (ABCL) raised $356 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO.

Who are AbCellera Biologics' major shareholders?

AbCellera Biologics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (8.29%), Capital World Investors (2.88%), Federated Hermes Inc. (1.07%), FIL Ltd (0.65%), Norges Bank (0.32%) and Intellectus Partners LLC (0.31%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends
.

How do I buy shares of AbCellera Biologics?

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABCL) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners